354 related articles for article (PubMed ID: 22761478)
1. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Colmers IN; Bowker SL; Majumdar SR; Johnson JA
CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone use and risk of bladder cancer: population based cohort study.
Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.
Turner RM; Kwok CS; Chen-Turner C; Maduakor CA; Singh S; Loke YK
Br J Clin Pharmacol; 2014 Aug; 78(2):258-73. PubMed ID: 24325197
[TBL] [Abstract][Full Text] [Related]
6. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
7. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
8. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Acta Diabetol; 2014 Feb; 51(1):91-101. PubMed ID: 23851465
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.
Bosetti C; Rosato V; Buniato D; Zambon A; La Vecchia C; Corrao G
Oncologist; 2013; 18(2):148-56. PubMed ID: 23345544
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
[TBL] [Abstract][Full Text] [Related]
13. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Loke YK; Singh S; Furberg CD
CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.
Colmers IN; Bowker SL; Johnson JA
Diabetes Metab; 2012 Dec; 38(6):475-84. PubMed ID: 23041441
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
18. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
Norris SL; Carson S; Roberts C
Curr Diabetes Rev; 2007 May; 3(2):127-40. PubMed ID: 18220664
[TBL] [Abstract][Full Text] [Related]
20. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
